DB06175InvestigationalSmall molecule
tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector containing the cDNA for a human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. It was under investigation... It was under investigation in clinical trials to treat Inflammatory Arthritis.
- Primary indication
- Investigated for use/treatment in arthritis and arthritic pain, rheumatoid arthritis, inflammatory disorders (unspecified), and gene therapy.Curator reviewed
- Code names
- TGAAC94
What you can answer from here — as of September 25, 2025
Which companies are running trials of TGAAC94, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account